ScoreWhy is Hainan Shuangcheng Pharmaceuticals Co., Ltd. ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%
- Poor long term growth as Net Sales has grown by an annual rate of -4.31% and Operating profit at -12.91% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
With a growth in Operating Profit of 205.72%, the company declared Outstanding results in Sep 25
- The company has declared positive results in Jan 70 after 7 consecutive negative quarters
- RAW MATERIAL COST(Y) Fallen by -161.23% (YoY)
- NET SALES(Q) Highest at CNY 84.78 MM
- OPERATING PROFIT(Q) Highest at CNY 17.18 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -16.12%, its profits have fallen by -75.2%
4
Underperformed the market in the last 1 year
- Even though the market (China Shanghai Composite) has generated returns of 15.17% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -16.12% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Hainan Shuangcheng Pharmaceuticals Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Hainan Shuangcheng Pharmaceuticals Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Hainan Shuangcheng Pharmaceuticals Co., Ltd.
-10.99%
1.28
56.13%
China Shanghai Composite
15.17%
1.02
14.86%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-4.31%
EBIT Growth (5y)
-12.91%
EBIT to Interest (avg)
-6.17
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.46
Sales to Capital Employed (avg)
0.32
Tax Ratio
0.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.26
EV to EBIT
-35.68
EV to EBITDA
-94.73
EV to Capital Employed
5.91
EV to Sales
20.75
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-16.56%
ROE (Latest)
-25.40%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend29What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -161.23% (YoY
NET SALES(Q)
Highest at CNY 84.78 MM
OPERATING PROFIT(Q)
Highest at CNY 17.18 MM
OPERATING PROFIT MARGIN(Q)
Highest at 20.26 %
PRE-TAX PROFIT(Q)
Highest at CNY 15.6 MM
NET PROFIT(Q)
Highest at CNY 15.78 MM
EPS(Q)
Highest at CNY 0.04
-3What is not working for the Company
INTEREST(9M)
At CNY 7.21 MM has Grown at 8%
CASH AND EQV(HY)
Lowest at CNY 73.97 MM
Here's what is working for Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Net Sales
At CNY 84.78 MM has Grown at 112.83%
over average net sales of the previous four periods of CNY 39.84 MMMOJO Watch
Near term sales trend is extremely positive
Net Sales (CNY MM)
Pre-Tax Profit
At CNY 15.6 MM has Grown at 165.19%
over average net sales of the previous four periods of CNY -23.93 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Net Profit
At CNY 15.78 MM has Grown at 190.17%
over average net sales of the previous four periods of CNY -17.5 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Net Sales
Highest at CNY 84.78 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Operating Profit
Highest at CNY 17.18 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Operating Profit Margin
Highest at 20.26 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at CNY 15.6 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Net Profit
Highest at CNY 15.78 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
EPS
Highest at CNY 0.04
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CNY)
Raw Material Cost
Fallen by -161.23% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Interest
At CNY 7.21 MM has Grown at 8%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Cash and Eqv
Lowest at CNY 73.97 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
